CHC – The Cancer & Hematology Centers

Cardiff Oncology CRDF-01E (EAP)

An Expanded Access Program of Onvansertib in Combination with FOLFIRI and Bevacizumab for the Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

PAL-E602-001 (Palleon)

Description:  A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Cancers   Target Patient Population:   Melanoma, Ovarian, Non Small Cell Lung Cancer, Colorectal and Pancreatic cancers Study Design:  Drug is given

Sym024-01 (Symphogen)

Description: A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination with Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies   Target Patient Population:  NSCLC (Adeno), Pancreatic, Cholangiocarcinoma, Metastatic Colorectal, Gastric, Esophageal, Mesothelioma and Squamous cell Head & Neck Study Design:  Both Drugs

TH1902-CTR-0001 (Theratechnologies, Inc.)

Description:  A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients with Advanced Solid Tumors and Expansion in Patients with Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer and Pancreatic Cancer   Target Patient Population:  Currently in Dose Escalation with all Solid Tumors.  Study Design:  Drug is administered IV every 3 weeks.